Received Apr 8, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | 2 | 54RR9 | — |
received 1st Bexsero dose on 2022, and the 2nd dose on 12-Mar-2026; This non-serious case was reported by a other health professional via call center representative and described the occurrence of drug dose administration interval too long in a 15-year-old male patient who received Men B NVS (Bexsero) (batch number 54RR9) for prophylaxis. Previously administered products included Bexsero (1st dose received on 2022). On 12-MAR-2026, the patient received the 2nd dose of Bexsero. On 12-MAR-2026, an unknown time after receiving Bexsero, the patient experienced drug dose administration interval too long (Verbatim: received 1st Bexsero dose on 2022, and the 2nd dose on 12-Mar-2026). The outcome of the drug dose administration interval too long was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 01-APR-2026 The patients were twins. This case is linked with US2026043383 reported by same reporter and different patient.; Sender's Comments: US-GSK-US2026043383:Same reporter/Different patient